RECRUITINGPhase 3INTERVENTIONAL
Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis
Clinical Study Evaluating the Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis
About This Trial
Evaluating the effect of the flavonoids combination (diosmin and hesperidin) as adjuvant therapy on patients with rheumatoid arthritis
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with mild to moderate disease activity.
- Patient age must be more than 18 years.
Who Should NOT Join This Trial:
- Pregnant and lactating females.
- Patients with liver, renal impairment or any other inflammatory diseases.
- Patients on TNF-α (tumor necrosis factor- α) or IL-1β (interleukin-1β) antagonists.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with mild to moderate disease activity.
* Patient age must be more than 18 years.
Exclusion Criteria:
* Pregnant and lactating females.
* Patients with liver, renal impairment or any other inflammatory diseases.
* Patients on TNF-α (tumor necrosis factor- α) or IL-1β (interleukin-1β) antagonists.
Treatments Being Tested
DRUG
Diosmin and Hesperidin Combination
Diosmin 450 mg and Hesperidin 50 mg Combination
Locations (1)
Alexandria university hospital
Alexandria, Egypt